Pfizer Vaccine – Covid-19 Vaccine
Pfizer Vaccine – Covid-19 Vaccine: The first US drug-based Pfizer Vaccine data from the clinical trials of the Covid-19 vaccine is found to be more than 90% effective. These results are significant as the U.S. Food and Drug Administration (FDA) is in a vaccine review later this month.
The Phase 3 trial of the BNT162b2 vaccine began on July 27 and has so far registered 43,538 participants, 38,955 of whom have received a second dose since November 8. The vaccine is developed using mRNA technology using messenger RNA molecules. mRNA, in this case, is coded to tell the cells to mimic the coronavirus spike protein novel.
Once the mRNA enters the body, the cells use their own instructions, forming copies of the spike protein, which stimulates the immune cells to make antibodies against them. Unlike many other vaccine candidates, mRNA vaccines have been artificially developed and do not require transplanting and doubling the virus, aimed at the most important part of the immune system.
After receiving the virus code, it is possible to develop the vaccine within weeks for pre-clinical testing, compared to the months it took for most traditional platforms. The vaccine was more than 90% effective in preventing covid-19 in participants who received a second dose, unlike a placebo.
Follow us on: Twitter
Follow us on: Facebook
Read Everyday Blogs at Daily Blog Day